Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Syndax Pharmaceuticals, Inc. (SNDX) had Return on Tangible Equity of -52.60% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$45.87M |
|
$-60.72M |
|
$2.10M |
|
$43.77M |
|
$103.30M |
|
$-57.43M |
|
$-3.29M |
|
$-60.72M |
|
$-60.72M |
|
$-60.72M |
|
$-60.72M |
|
$-60.72M |
|
$-60.72M |
|
$-57.43M |
|
$-59.77M |
|
86.62M |
|
86.62M |
|
$-0.70 |
|
$-0.70 |
|
| Balance Sheet Financials | |
$529.83M |
|
$0.13M |
|
$21.96M |
|
$551.79M |
|
$114.19M |
|
$320.99M |
|
$322.18M |
|
$436.36M |
|
$115.43M |
|
$115.43M |
|
$115.43M |
|
86.91M |
|
| Cash Flow Statement Financials | |
$-253.49M |
|
$208.46M |
|
$7.76M |
|
$154.30M |
|
$117.03M |
|
$-37.27M |
|
$36.25M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.64 |
|
-- |
|
-- |
|
0.74 |
|
2.98 |
|
95.42% |
|
-125.19% |
|
-125.19% |
|
-- |
|
-132.36% |
|
-132.36% |
|
$-253.62M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
0.08 |
|
1.11 |
|
80.72 |
|
-52.60% |
|
|
Return on Tangible Equity |
-52.60% |
-11.00% |
|
-13.91% |
|
$1.33 |
|
$-2.93 |
|
$-2.93 |
|